These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16358442)

  • 21. Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective.
    Viana JM
    Conn J Int Law; 2002; 17(2):311-8. PubMed ID: 12688298
    [No Abstract]   [Full Text] [Related]  

  • 22. Academic patents and access to medicines in developing countries.
    Sampat BN
    Am J Public Health; 2009 Jan; 99(1):9-17. PubMed ID: 19008514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patents and access to drugs in developing countries: an ethical analysis.
    Sterckx S
    Dev World Bioeth; 2004 May; 4(1):58-75. PubMed ID: 15086374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Access to essential medicines: a Hobbesian social contract approach.
    Ashcroft RE
    Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Priceless goods: how should life-saving drugs be priced?
    Maitland I
    Bus Ethics Q; 2002 Oct; 12(4):451-80. PubMed ID: 12708456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Balancing access to pharmaceuticals with patent rights.
    Nicol D
    Monash Bioeth Rev; 2003 Apr; 22(2):50-62. PubMed ID: 15069957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. It is not unethical, though it is often unwise, to override patents.
    Leventer H
    Am J Bioeth; 2002; 2(3):50-1. PubMed ID: 12230860
    [No Abstract]   [Full Text] [Related]  

  • 28. More drugs, less protection.
    Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521
    [No Abstract]   [Full Text] [Related]  

  • 29. Who's in the business of saving lives?
    Lee Chang P
    J Med Philos; 2006 Oct; 31(5):465-82. PubMed ID: 17079208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Questions raised about whether compulsory licenses get best prices.
    Owens B
    Nat Med; 2015 Apr; 21(4):300. PubMed ID: 25849264
    [No Abstract]   [Full Text] [Related]  

  • 31. Does the pharmaceutical sector have a coresponsibility for the human right to health?
    Schroeder D
    Camb Q Healthc Ethics; 2011 Apr; 20(2):298-308. PubMed ID: 21435305
    [No Abstract]   [Full Text] [Related]  

  • 32. The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia.
    Faunce TS; Tomossy GF
    Monash Bioeth Rev; 2005 Apr; 24(2):38-42. PubMed ID: 16208881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Out-licensing: a practical approach for improvement of access to medicines in poor countries.
    Friedman MA; den Besten H; Attaran A
    Lancet; 2003 Jan; 361(9354):341-4. PubMed ID: 12559883
    [No Abstract]   [Full Text] [Related]  

  • 34. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sparks fly over patents and vital drugs at world health assembly.
    Kapp C
    Lancet; 2003 May; 361(9372):1873. PubMed ID: 12788578
    [No Abstract]   [Full Text] [Related]  

  • 36. Introduction: pharmaceutical innovation: law & the public's health.
    Outterson K
    J Law Med Ethics; 2009; 37(2):173-5. PubMed ID: 19493064
    [No Abstract]   [Full Text] [Related]  

  • 37. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S
    Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmaceuticals and medical devices: business practices.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
    [No Abstract]   [Full Text] [Related]  

  • 39. In the high court of South Africa, case no. 4138/98: the global politics of access to low-cost AIDS drugs in poor countries.
    Barnard D
    Kennedy Inst Ethics J; 2002 Jun; 12(2):159-74. PubMed ID: 12476916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
    Sykes AO
    Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.